News

10 June 24

Alzheimer’s drug with modest benefits wins backing of FDA advisers

Donanemab, an Alzheimer’s drug, received unanimous backing from FDA advisors for its ability to slow cognitive decline.

18 April 24

The differences between normal aging and dementia

It is important to distinguish between memory loss related to normal aging and signs of serious neurocognitive disorders such as Alzheimer’s disease.

12 January 24

San Diego will be 1 of the first cities to use new treatment for Alzheimer’s disease

Exciting breakthrough for Alzheimer’s!

9 June 23

FDA advisers vote that lecanemab shows benefit as an Alzheimer’s treatment

‘’The Alzheimer’s drug lecanemab has received unanimous support from an advisory panel for the US Food and Drug Administration, which deemed it to have ‘clinical benefit’ for the treatment of the disease. This positive vote paves the way for the medication to be considered for full FDA approval. Lecanemab, known as Leqembi, is one of the first drugs that appears to slow cognitive decline in dementia patients by targeting amyloid beta. Patient groups and experts hope that this milestone decision will ensure access to FDA-approved therapies without barriers, similar to treatments for other serious conditions. The FDA is expected to announce its decision by July 6.’’

3 May 23

Third Amyloid plaque clearing drug against AD in two years is reason for hope

On May 3rd, 2023 Ely Lily announced positive results from their phase 3 clinical trial (TRAILBLAZER-ALZ2) for the drug, Donanemab, a monoclonal antibody (Lilly’s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease, n.d.).

14 March 23

Simufilam aids cognition in 47% of Alzheimer’s patients in Phase 2 study

A Phase 2 clinical trial of simufilam, an experimental medication for Alzheimer’s disease, showed cognitive benefits in nearly half of the patients after one year of treatment. The medication was particularly effective for those in the early stages of the disease. Simufilam also demonstrated positive effects on depression and dementia-related behaviors. Phase 3 trials are currently enrolling participants to further investigate the safety and efficacy of simufilam. The goal is to develop an effective treatment for Alzheimer’s, a progressive disease characterized by memory loss, confusion, and cognitive decline.

Les jasettes du premier jeudi

Le diabète peut-il être prévenu?

The Thursday Chats

What is home care and how to access it

Ottawa

Ottawa Women’s Show

Gatineau

Le Salon FADOQ Distinction 50 +

Ottawa

Diabetes Awareness Day

Les jasettes du premier jeudi

Les saines habitudes de vie aux services du cerveau